Diet during pregnancy and risk of preeclampsia or gestational hypertension

Research output: Contribution to journalJournal articleResearchpeer-review

  • Emily Oken
  • Yi Ning
  • Sheryl L Rifas-Shiman
  • Janet W Rich-Edwards
  • Olsen, Sjurdur F.
  • Matthew W Gillman

PURPOSE: We sought to examine associations of first-trimester intake of calcium, n-3 and n-6 fatty acids, trans fatty acids, magnesium, folate, and vitamins C, D, and E with preeclampsia (PE) and gestational hypertension (GH).

METHODS: We studied associations of diet with PE or GH among 1718 women in the prospective cohort study Project Viva, using logistic regression and adjusting for maternal age, prepregnancy body mass index, first trimester systolic blood pressure, race/ethnicity, education, and parity. We assessed first-trimester diet using a validated semiquantitative food frequency questionnaire.

RESULTS: A total of 59 (3%) women developed PE, and 119 developed (7%) GH. We found a somewhat-lower risk of PE associated with higher intake of the elongated n-3 fatty acids docosahexaenoic and eicosapentaenoic acids (odds ratio [OR] 0.84, 95% confidence interval [95% CI]: 0.69-1.03 per 100 mg/day), fish (OR 0.91, 95% CI 0.75-1.09 per serving/day), and the ratio of docosahexaenoic + eicosapentaenoic to arachadonic acid (OR 0.82, 95% CI 0.66-1.01). We did not observe a lower risk of GH or PE with a greater intake of calcium; vitamin C, D, or E; milk; magnesium; folate; or with lower intake of n-6 or trans fatty acids.

CONCLUSIONS: Our results support a potential benefit for elongated n-3 fatty acids in preventing preeclampsia.

Original languageEnglish
JournalAnnals of Epidemiology
Volume17
Issue number9
Pages (from-to)663-8
Number of pages6
ISSN1047-2797
DOIs
Publication statusPublished - 2007
Externally publishedYes

    Research areas

  • Adult, Diet Surveys, Dietary Supplements, Female, Humans, Hypertension, Pregnancy-Induced/epidemiology, Massachusetts/epidemiology, Pre-Eclampsia/epidemiology, Pregnancy, Pregnancy Trimester, First, Prospective Studies, Risk Assessment

ID: 308036680